Calvera presents Phase 2b data for CLV-226 in atopic dermatitis
Investigational antibody met its primary endpoint at week 16, with skin clearance maintained through week 32.
Read more →
Home/News
Calvera and Northfield Genomics sign gene therapy manufacturing agreement
Multi-year collaboration expands viral vector capacity for the rare disease pipeline.
Read more →Calvera reports second-quarter 2026 results
Revenue grew 14% on strong demand for Dermavia and Cardelle; full-year outlook raised.
Read more →Regulators accept filing for berolumab-cvra in first-line HER-low breast cancer
Priority review granted, with a decision expected in the second quarter of 2027.
Read more →Calvera opens new research campus in Raleigh, North Carolina
The 400,000 square foot site will house 900 scientists and a clinical-scale manufacturing suite.
Read more →Late-breaking data for emzaratinib presented at oncology congress
Adjuvant study shows a 41% reduction in risk of recurrence versus placebo.
Read more →Calvera reports first-quarter 2026 results
Revenue of $4.3 billion; pipeline advanced with two Phase 3 starts.
Read more →Calvera publishes 2025 Responsibility Report
Company reports 32% cut in operational emissions and expanded patient-access programs in 40 countries.
Read more →Calvera licenses RNA platform from Halden Bio
Agreement adds liver-targeted delivery technology for cardiometabolic programs.
Read more →